Marshall Wace
STML

Marshall Wace’s Stemline Therapeutics, Inc. STML Stock Holding History

Marshall Wace’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,354
Closed -$35K – 2251
2019
Q3 		$35K Buy
+3,354
New +$43.9K ﹤0.01% 1542
2019
Q1 		– Sell
-26,763
Closed -$254K – 2211
2018
Q4 		$254K Buy
+26,763
New +$347K ﹤0.01% 1243

Other funds holding STML

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Marshall Wace's STML Position: Q4 2019 in Review

Marshall Wace sold out of Stemline Therapeutics, Inc. (STML) in Q4 2019, closing a stake of 3,354 shares — an estimated $35K sold.

Marshall Wace first reported a position in STML in Q4 2018 and held it in 2 quarters. The position peaked at $254K in Q4 2018. 99 funds tracked by Wall St. Rank hold STML as of Q4 2019.

  • Marshall Wace reported no remaining Stemline Therapeutics, Inc. position as of Q4 2019 after selling out during the quarter.
  • Marshall Wace sold 3,354 Stemline Therapeutics, Inc. shares in Q4 2019, an estimated $35K.
  • Marshall Wace first reported a position in Stemline Therapeutics, Inc. in Q4 2018 and held it in 2 quarters.
  • Marshall Wace's Stemline Therapeutics, Inc. position peaked at $254K in Q4 2018.
  • 99 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2019.

Based on Marshall Wace's 13F filing for Q4 2019, filed 14 Feb 2020.